Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR)
It is a hydroxyethyl ether-substituted derivative of rapamycin with improved pharmacokinetic and pharmacodynamic properties
It inhibits both mTORC1 and mTORC2 complexes by binding to FK506-binding protein (FKBP-12), which then binds to mTOR, leading to complex destabilization and blocked kinase function (Zeng et al.; Lebwohl et al.; Sedrani et al.; Huang & Houghton)
Inhibits cell proliferation, metabolism, and angiogenesis in a variety of cancers using in vitro and in vivo models (Zhu et al.; Lane et al.; O'Reilly et al.; Lebwohl et al.)
Acts as an immunosuppressive agent in the context of organ transplantation (Lebwohl et al.; Wullschleger et al.)
Caractéristiques techniques
Marque
STEMCELL Technologies
Réf. B-LABO
BL-RE-126450
Réf. fabricant
17180172
CAS
159351-69-6
Synonyme
RAD001; SDZ-RAD; Xience
Quantité
10 mg
Formule moléculaire
C<sub>53</sub>H<sub>83</sub>NO<sub>14</sub>
Pureté
≥95%
Une question, une configuration particulière ? Contactez-nous pour un devis.
